[go: up one dir, main page]

CN114555586A - 新颖的krasg12c蛋白抑制剂及其制备方法和用途 - Google Patents

新颖的krasg12c蛋白抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN114555586A
CN114555586A CN202080070490.6A CN202080070490A CN114555586A CN 114555586 A CN114555586 A CN 114555586A CN 202080070490 A CN202080070490 A CN 202080070490A CN 114555586 A CN114555586 A CN 114555586A
Authority
CN
China
Prior art keywords
methyl
alkyl
ethyl
halogen
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080070490.6A
Other languages
English (en)
Other versions
CN114555586B (zh
Inventor
张龙
宋国伟
杨智亮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN114555586A publication Critical patent/CN114555586A/zh
Application granted granted Critical
Publication of CN114555586B publication Critical patent/CN114555586B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

属于药物化学领域，涉及新颖的KRAS G12C蛋白抑制剂及其制备方法和用途。具体而言，提供了一种具有式(I)结构的化合物，其可以作为高效的KRAS G12C蛋白抑制剂，具有抗肿瘤、抗增生性疾病、抗炎、抗自身免疫性疾病等多种药理活性。
Figure DDA0003584082850000011

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080070490.6A 2019-10-10 2020-10-09 Krasg12c蛋白抑制剂及其制备方法和用途 Active CN114555586B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019109594915 2019-10-10
CN201910959491 2019-10-10
CN201911120362 2019-11-15
CN2019111203623 2019-11-15
PCT/CN2020/120028 WO2021068898A1 (zh) 2019-10-10 2020-10-09 新颖的kras g12c蛋白抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN114555586A true CN114555586A (zh) 2022-05-27
CN114555586B CN114555586B (zh) 2023-06-23

Family

ID=75437768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070490.6A Active CN114555586B (zh) 2019-10-10 2020-10-09 Krasg12c蛋白抑制剂及其制备方法和用途

Country Status (3)

Country Link
US (1) US20230257374A1 (zh)
CN (1) CN114555586B (zh)
WO (1) WO2021068898A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
EP3890716A4 (en) 2018-12-05 2022-12-21 Mirati Therapeutics, Inc. POLYTHERAPIES
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
EP4076418A4 (en) 2019-12-20 2024-01-24 Mirati Therapeutics, Inc. Sos1 inhibitors
MX2023002942A (es) 2020-09-11 2023-05-22 Mirati Therapeutics Inc Formas cristalinas de un inhibidor de kras g12c.
IL301524A (en) 2020-09-23 2023-05-01 Erasca Inc Tricyclic pyridones and pyrimidones
MX2023007084A (es) 2020-12-15 2023-08-30 Mirati Therapeutics Inc Inhibidores de pan-kras de azaquinazolina.
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022223020A1 (zh) * 2021-04-23 2022-10-27 清华大学 靶向活化与失活态kras g12d的抑制剂
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
TW202317580A (zh) * 2021-06-18 2023-05-01 大陸商南京燧坤智能科技有限公司 用作ｋｒａｓ ｇ１２ｄ抑制劑的氘代化合物
JP2024529020A (ja) * 2021-08-06 2024-08-01 レイゼビオ，インク． 細胞内ｋｒａｓ ｇ１２ｃタンパク質を標的とするための共有結合剤を含むコンジュゲート
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2025067459A2 (en) 2023-09-29 2025-04-03 D3 Bio (Wuxi) Co., Ltd. Therapies for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190144444A1 (en) * 2017-11-15 2019-05-16 Mirati Therapeutics, Inc. Kras g12c inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444509B1 (ko) * 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
ES3004338T3 (en) * 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
ES3017461T3 (en) * 2018-09-10 2025-05-13 Mirati Therapeutics Inc Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190144444A1 (en) * 2017-11-15 2019-05-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019099524A1 (en) * 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王世真, 中国协和医科大学出版社 *

Also Published As

Publication number Publication date
US20230257374A1 (en) 2023-08-17
CN114555586B (zh) 2023-06-23
WO2021068898A1 (zh) 2021-04-15

Similar Documents

Publication Publication Date Title
CN114555586B (zh) Krasg12c蛋白抑制剂及其制备方法和用途
CN112430234B (zh) 一种新型kras g12c蛋白抑制剂及其制备方法和用途
US10851092B2 (en) Pyridine compound
TR201810399T4 (tr) İndolamin 2,3-dioksijenaz (ıdo) inhibitörleri.
KR20150129010A (ko) Ido 억제제
AU2016292450A1 (en) Aniline pyrimidine derivatives and uses thereof
JP2010530883A (ja) ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
KR20110066212A (ko) 이치환된 프탈라진 헷지호그 경로 길항제
US20240166606A1 (en) Multi-targeted tyrosine kinase inhibitors and their pharmaceutical uses
CN108570038B (zh) 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
CN114728938A (zh) 作为prmt5抑制剂的四氢异喹啉螺环化合物
CN116375707A (zh) Menin抑制剂及其用途
CN101921268B (zh) 5-噻唑酰胺类化合物及生物学应用
CN112538084B (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
CN116867779A (zh) 用于癌症治疗的KRas抑制剂
WO2021259049A1 (zh) 吲哚类衍生物及其制备方法和应用
CN103936762B (zh) 吗啉并喹啉类化合物，其制备方法和用途
EP4225753B1 (en) Potent and selective compounds as serotonin 1b receptor modulators
KR20130118731A (ko) 항증식성 질환 치료에 사용하기 위한 ｐｉ3ｋ 억제제로서 피페라지노트리아진
CN113135898B (zh) 一种抗癌喹喔啉嘧啶胺杂环化合物及其制备方法和应用
CN111836819A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
CN115768757B (zh) Cd206调节剂及其用途和制备方法
CN110526907B (zh) 苯并噁嗪酮类衍生物及其应用
WO2025148870A1 (zh) Ras抑制剂
TW202535380A (zh) 吡唑羧酸衍生物及其在醫藥上的應用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant